Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) have been given an average rating of “Moderate Buy” by the nine analysts that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have covered the stock in the last year is $7.33.

Several brokerages recently weighed in on AMLX. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Amylyx Pharmaceuticals in a research report on Thursday, December 5th. Leerink Partners set a $4.00 price target on shares of Amylyx Pharmaceuticals and gave the company a “market perform” rating in a report on Friday, October 18th. Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 18th. Robert W. Baird upgraded shares of Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $3.00 to $11.00 in a research note on Monday, November 18th. Finally, Bank of America raised shares of Amylyx Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $4.20 to $10.00 in a research note on Wednesday, October 23rd.

Amylyx Pharmaceuticals Price Performance

NASDAQ AMLX opened at $3.45 on Wednesday. The stock has a market capitalization of $236.50 million, a PE ratio of -0.90 and a beta of -0.53. Amylyx Pharmaceuticals has a 1-year low of $1.58 and a 1-year high of $19.95. The business has a 50 day simple moving average of $4.47 and a two-hundred day simple moving average of $3.54.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 7,471 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $4.04, for a total value of $30,182.84. Following the sale, the chief executive officer now owns 3,176,788 shares in the company, valued at approximately $12,834,223.52. This represents a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 11.70% of the stock is owned by corporate insiders.

Institutional Trading of Amylyx Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its holdings in Amylyx Pharmaceuticals by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,094 shares of the company’s stock worth $42,000 after acquiring an additional 5,104 shares in the last quarter. Algert Global LLC acquired a new position in Amylyx Pharmaceuticals in the second quarter valued at approximately $47,000. Hsbc Holdings PLC grew its holdings in shares of Amylyx Pharmaceuticals by 57.9% during the 2nd quarter. Hsbc Holdings PLC now owns 76,261 shares of the company’s stock worth $150,000 after purchasing an additional 27,954 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter valued at about $156,000. Finally, Maven Securities LTD lifted its holdings in shares of Amylyx Pharmaceuticals by 300.0% in the 2nd quarter. Maven Securities LTD now owns 100,000 shares of the company’s stock worth $190,000 after acquiring an additional 75,000 shares during the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.